Robert C. Doebele

ScholarGPS® ID: 36247278633527

Affiliation
University of Colorado Anschutz Medical Campus, Aurora, United States
Affiliation History

Field
Medicine
Discipline
Oncology
Top Specialties
Cancer | Lung Cancer | Non-small-cell Lung Carcinoma | Thorax | Neoplasm | Epidermal Growth Factor Receptor | Oncogene | Targeted Therapy | Mutation | Protein Kinase Inhibitor | Chemotherapy | Tyrosine Kinase | Fusion Gene | Tyrosine Kinase Inhibitor | Lymphoma
Metrics Summary
Publication Count
246
Predicted Citations
22,413
Predicted h-index
68
Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

  • Publications
  • Books
  • Patents
  • NIH/NSF
You must register and claim your profile to add or remove publications from it.
... publications
FILTER BY:
Year
Type
Specialty
Affiliations
Access
Co-Authors
Add
Delete
MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling (journal article)
Chen, Nan | Tyler, Logan C. | Le, Anh T. | Welsh, Eric A. | Fang, Bin | Elliott, Andrew | Davies, Kurtis D. | Danhorn, Thomas | Riely, Gregory J. | Ladanyi, Marc | ... | Doebele, Robert C.
Molecular Cancer Therapeutics, volume 23, issue 1, pages 92-105 (2024).
10.1158/1535-7163.MCT-23-0218
Cite | Source
Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression (journal article)
Peters, Tara L. | Chen, Nan | Tyler, Logan C. | Le, Anh T. | Dimou, Anastasios | Doebele, Robert C.
Thoracic Cancer, volume 14, issue 33, pages 3259-3265 (2023).
10.1111/1759-7714.15116
Cite | Source
P2.11-04 A Phase 1B Trial of Tarloxotinib and Sotorasib in Lung Cancer Patients with KRAS G12C Mutations (journal article)
Alexander, M. | Tirunagaru, V.G. | Doebele, R.C. | Wrangle, J.M.
Journal of Thoracic Oncology, volume 18, issue 11, pages S361- (2023).
10.1016/j.jtho.2023.09.634
Cite | Source
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification (journal article)
Elkrief, Arielle | Odintsov, Igor | Markov, Vladimir | Caeser, Rebecca | Sobczuk, Pawel | Tischfield, Sam E. | Bhanot, Umesh | Vanderbilt, Chad M. | Cheng, Emily H. | Drilon, Alexander | ... | Ladanyi, Marc
Journal of Thoracic Oncology, volume 18, issue 9, pages 1165-1183 (2023).
10.1016/j.jtho.2023.05.007
Cited by (4) | Cite | Source
A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes (journal article)
Schubert, Laura | Le, Anh T. | Hinz, Trista K. | Navarro, Andre C. | Nelson-Taylor, Sarah K. | Nemenoff, Raphael A. | Heasley, Lynn E. | Doebele, Robert C.
Biology Open, volume 12, issue 8 (2023).
10.1242/bio.059994
Cited by (1) | Cite | Source
Differential Chemoproteomics Reveals MARK2/3 as Cell Migration‐Relevant Targets of the ALK Inhibitor Brigatinib (journal article)
Hu, Qianqian | Liao, Yi | Cao, Jessica | Fang, Bin | Yun, Sang Y. | Kinose, Fumi | Haura, Eric B. | Lawrence, Harshani R. | Doebele, Robert C. | Koomen, John M. | Rix, Uwe
ChemBioChem, volume 24, issue 11 (2023).
10.1002/cbic.202200766
Cited by (2) | Cite | Source
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types (journal article)
Schubert, Laura | Elliott, Andrew | Le, Anh T. | Estrada-Bernal, Adriana | Doebele, Robert C. | Lou, Emil | Borghaei, Hossein | Demeure, Michael J. | Kurzrock, Razelle | Reuss, Joshua E. | ... | Liu, Stephen V.
Frontiers in Oncology, volume 13 (2023).
10.3389/fonc.2023.1115405
Cited by (4) | Cite | Source
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas (journal article)
Gounder, Mrinal M. | Bauer, Todd M. | Schwartz, Gary K. | Weise, Amy M. | LoRusso, Patricia | Kumar, Prasanna | Tao, Ben | Hong, Ying | Patel, Parul | Lu, Yasong | ... | Hong, David S.
Journal of Clinical Oncology, volume 41, issue 9, pages 1714-1724 (2023).
10.1200/JCO.22.01285
Cited by (28) | Cite | Source
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression (journal article)
Chuang, Tzu-Po | Lai, Wei-Yun | Gabre, Jonatan L. | Lind, Dan E. | Umapathy, Ganesh | Bokhari, Abdulmalik A. | Bergman, Bengt | Kristenson, Linnea | Thorén, Fredrik B. | Le, Anh | ... | Hallberg, Bengt
Proceedings of the National Academy of Sciences, volume 120, issue 8 (2023).
10.1073/pnas.2216479120
Cited by (7) | Cite | Source
Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway (journal article)
Priest, Katherine | Le, Anh | Gebregzabheir, Amanuail | Nijmeh, Hala | Reis, Gregory B. | Mandell, Melanie | Davies, Kurtis D. | Lawrence, Carolyn | O’Donnell, Emily | Doebele, Robert C. | ... | Schenk, Erin L.
npj Precision Oncology, volume 7, issue 1 (2023).
10.1038/s41698-023-00349-0
Cited by (7) | Cite | Source
MET gene amplification is a mechanism of resistance to entrectinib in ROS1 + NSCLC (journal article)
Tyler, Logan C. | Le, Anh T. | Chen, Nan | Nijmeh, Hala | Bao, Liming | Wilson, Timothy R. | Chen, David | Simmons, Brian | Turner, Kristen M. | Perusse, Dean | ... | Doebele, Robert C.
Thoracic Cancer, volume 13, issue 21, pages 3032-3041 (2022).
10.1111/1759-7714.14656
Cited by (9) | Cite | Source
Combination of MDM2 inhibition with milademetan and MEK inhibition leads to improved anti-tumor activity in cancer models harboring WT TP53 (journal article)
Tirunagaru, V. | Singh, K. | Pei, X. | Doebele, R.C.
European Journal of Cancer, volume 174 (2022).
10.1016/S0959-8049(22)00858-9
Cite | Source
Milademetan is a highly potent MDM2 inhibitor in TP53 wild-type (p53 WT) models of Merkel cell carcinoma (MCC) (journal article)
Ananthapadmanabhan, Varsha | Frost, Thomas C. | Soroko, Kara M. | Knott, Aine | Magliozzi, Brianna | Gokhale, Prafulla C. | Tirunagaru, Vijaya | Doebele, Robert C. | DeCaprio, James A.
Journal of Investigative Dermatology, volume 142, issue 10, pages 2837- (2022).
10.1016/j.jid.2022.08.004
Cite | Source
EP16.03-012 Novel Human-derived EML4-ALK Fusion cell lines identify ribonucleotide reductase RRM2 as a Target of Activated ALK in NSCLC (journal article)
Umapathy, G. | Bokhari, A. | Lai, W.-Y. | Le, A. | Chuang, T.-P. | Fransson, S. | Martinsson, T. | Van den Eynden, J. | Doebele, R. | Palmer, R.H. | Hallberg, B.
Journal of Thoracic Oncology, volume 17, issue 9, pages S591- (2022).
10.1016/j.jtho.2022.07.1073
Cite | Source
A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53 -wild type and MDM2 -amplified advanced or metastatic solid tumors (MANTRA-2). (journal article)
Dumbrava, Ecaterina Elena | Hanna, Glenn J. | Cote, Gregory Michael | Stinchcombe, Tom | Johnson, Melissa Lynne | Chen, Christopher | Devarakonda, Siddhartha | Shah, Naisargee | Xu, Feng | Doebele, Robert Charles | Gounder, Mrinal M.
Journal of Clinical Oncology, volume 40, issue 16_suppl, pages TPS3165-TPS3165 (2022).
10.1200/JCO.2022.40.16_suppl.TPS3165
Cited by (5) | Cite | Source
Using CDKN2A loss in the context of wildtype TP53 to predict sensitivity for the MDM2 inhibitor milademetan. (journal article)
Tirunagaru, Vijaya G | Xu, Feng | Hinz, Trista | Heasley, Lynn | Bryce, Richard | Vellanki, Avanish | Ku, Nora | Doebele, Robert Charles
Journal of Clinical Oncology, volume 40, issue 16_suppl, pages 3136-3136 (2022).
10.1200/JCO.2022.40.16_suppl.3136
Cite | Source
Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib (journal article)
Dziadziuszko, Rafal | Hung, Tiffany | Wang, Kun | Choeurng, Voleak | Drilon, Alexander | Doebele, Robert C. | Barlesi, Fabrice | Wu, Charlie | Dennis, Lucas | Skoletsky, Joel | ... | Wilson, Timothy R.
Molecular Oncology, volume 16, issue 10, pages 2000-2014 (2022).
10.1002/1878-0261.13214
Cited by (10) | Cite | Source
Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA (journal article)
Stinchcombe, Thomas E. | Wang, Xiaofei | Doebele, Robert C. | Drusbosky, Leylah M. | Gerber, David E. | Horn, Leora | Bertino, Erin M. | Liu, Geoff | Villaruz, Liza C. | Ross Camidge, D.
Lung Cancer, volume 165 (2022).
10.1016/j.lungcan.2021.12.019
Cited by (2) | Cite | Source
Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1 + NSCLC (journal article)
Doebele, Robert C | Perez, Laura | Trinh, Huong | Martinec, Michael | Martina, Reynaldo | Riehl, Todd | Krebs, Matthew G | Meropol, Neal J | Wong, William B | Crane, Gracy
Journal of Comparative Effectiveness Research, volume 10, issue 17, pages 1271-1282 (2021).
10.2217/cer-2021-0131
Cited by (12) | Cite | Source
Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC (journal article)
Peters, T. L. | Patil, T. | Le, A. T. | Davies, K. D. | Brzeskiewicz, P. M. | Nijmeh, H. | Bao, L. | Camidge, D. R. | Aisner, D. L. | Doebele, R. C.
npj Precision Oncology, volume 5, issue 1 (2021).
10.1038/s41698-021-00231-x
Cited by (5) | Cite | Source